Predictive factors for the outcome of radioiodine therapy in patients with benign thyroid diseases

Abstract

Purpose Radioiodine therapy (RIT) of benign thyroid diseases is an established therapy. This study aimed to identify factors predictive for outcome in patients with non-toxic goiter (NTG), unifocal (UFA), multifocal (MUFA) or diffuse autonomy (DISA) and Graves’ disease (GD).

Methods Retrospective analysis of 205 patients with benign thyroid disease (54 NTG, 46 MUFA, 24 DISA, 26 UFA, 55 GD) who underwent RIT. Follow up time was 12 months for determining treatment outcome.

Results The type of disease was predictive for volume reduction after 12 months (NTS 66%, DISA 67%, MUFA 58%, UFA 51%, GD 71%, p<0.001) and post-treatment hypothyroidism (NTS 48%, DISA 33%, MUFA 15%, UFA 15%, p=0.006). Initial volume, intra-therapeutic uptake and intra-therapeutic half-life were independent prognostic factors for volume reduction 12 months after RIT. In patients with NTG, UFA, MUFA, DISA post-treatment hypothyroidism was significantly correlated with extent of volume reduction 12 months after RIT, achieved dose, higher pre-therapeutic TSH values and younger age. Two different strategies for pre-therapeutic dosimetry used in MUFA showed no differences regarding the therapeutic outcome. In GD, effective half-life, initial volume and Graves’ ophthalmopathy were predictive for treatment failure.

Conclusion Reduction of thyroid volume and the percentage of hypothyroid patients one year after RIT was primarily dependent on the type of disease. In MUFA and DISA we could identify volume reduction after 3 months as a reliable predictor for hypothyroidism while in patients with GD a short intra-therapeutic half-life, a large pre-therapeutic volume and active Graves’ ophtalmopathy were relevant predictors for treatment failure suggesting an intensified follow-up scheme in these patients.

Keywords

radioiodine therapy - benign thyroid disease - Graves’ disease - nontoxic goiter - unifocal autonomy - multifocal autonomy

Publication History

Received: 09 April 2023

Accepted: 12 October 2023

Article published online:
08 January 2024

• References

• 1 Hampel R, Bennohr G, Gordalla A. et al. Urinary iodine excretion in German adults in 2005 meets WHO target. Med Klin (Munich) 2009; 104 (06) 425-428 DOI: 10.1007/s00063-009-1090-y. (PMID: 19533048)
• 2 Meisinger C, Ittermann T, Wallaschofski H. et al. Geographic variations in the frequency of thyroid disorders and thyroid peroxidase antibodies in persons without former thyroid disease within Germany. Eur J Endocrinol 2012; 167 (03) 363-371
• 3 Volzke H, Ludemann J, Robinson DM. et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13 (08) 803-810 DOI: 10.1089/105072503768499680. (PMID: 14558922)
• 4 J. R. Siewert MR, V. Schumpelick. J. R. Siewert, M. Rothmund, V. Schumpelick. 2007.
• 5 Grünwald F, Derwahl K-M. Diagnostik und Therapie von Schilddrüsenerkrankungen. In: . 2014: 109
• 6 Dederichs B, Otte R, Klink JE. et al. Volume reduction of the thyroid after radioiodine therapy in patients with autonomous goiter and Basedow’s goiter. Nuklearmedizin 1996; 35 (05) 164-169
• 7 Bonnema SJ, Bertelsen H, Mortensen J. et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999; 84 (10) 3636-3641
• 8 Manders JM, Corstens FH. Radioiodine therapy of euthyroid multinodular goitres. Eur J Nucl Med Mol Imaging 2002; 29: S466-470 DOI: 10.1007/s00259-002-0876-4. (PMID: 12192547)
• 9 Peters H, Fischer C, Bogner U. et al. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996; 26 (01) 59-63 DOI: 10.1046/j.1365-2362.1996.98243.x. (PMID: 8682157)
• 10 Murakami Y, Takamatsu J, Sakane S. et al. Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81 (09) 3257-3260
• 11 Albino CC, Graf H, Sampaio AP. et al. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs 2008; 17 (12) 1781-1786 DOI: 10.1517/13543780802501325. (PMID: 19012495)
• 12 Ceccarelli C, Bencivelli W, Vitti P. et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf) 2005; 62 (03) 331-335 DOI: 10.1111/j.1365-2265.2005.02218.x. (PMID: 15730415)
• 13 Nakatake N, Fukata S, Tajiri J. Prediction of post-treatment hypothyroidism using changes in thyroid volume after radioactive iodine therapy in adolescent patients with Graves’ disease. Int J Pediatr Endocrinol 2011; 2011: 14 DOI: 10.1186/1687-9856-2011-14. (PMID: 22060749)
• 14 Wesche MF, Tiel VBMM, Lips P. et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86 (03) 998-1005
• 15 Le Moli R, Wesche MF, Tiel-Van Buul MM. et al. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999; 50 (06) 783-789
• 16 Kaniuka-Jakubowska S, Lewczuk A, Mizan-Gross K. et al. Large multinodular goiter--outpatient radioiodine treatment. Endokrynol Pol 2015; 66 (04) 301-307 DOI: 10.5603/EP.2015.0038. (PMID: 26323466)